National

Covid-19 vaccines: India supplied 165 lakh doses on commercial basis

Our Bureau New Delhi | Updated on February 12, 2021

Discussions on India’s participation in Colombo port still underway

India has supplied a total of 229.7 lakh doses of Covid-19 vaccines to the global community of which 165 lakh doses have been supplied on a commercial basis while 64.7 lakh doses have been given as grants, the MEA has said.

Morocco got the biggest supply of 60 lakhs doses of the vaccine on a commercial basis, followed by Bangladesh (50 lakh), Brazil (20 lakh), Myanmar (20 lakh), South Africa (10 lakh), Kuwait (2 lakh), UAE (2 lakh), Egypt (50,000) and Algeria (50,000).

Countries that received the vaccine as gifts include Banglades(20 lakh doses), Myanmar(17 lakh), Nepal (10 lakh ), Bhutan (1.5 lakh), Maldives(1 lakh), Mauritius(1 lakh), Seychelles(50,000), Sri Lanka(5 lakh), Bahrain (1 lakh), Oman (1 lakh), Afghanistan (5 lakh), Barbados (1 lakh) and Dominica (70,000). “ In the coming weeks, vaccines will be supplied to more countries in Africa, Latin America, CARICOM and Pacific Island states,” said MEA spokesperson Anuran Srivastava.”

Decisions on these supplies will, of course, be calibrated as per domestic production and the requirements of the national vaccination programme, he added.

On the recent change in stance of the Sri Lankan government regarding investments in the Colombo port, the spokesperson said that India’s interest for participation in the Colombo port was a long standing one since most goods handled there are from and to India. “We had, in principle, agreement from the Sri Lankan Government in this regard. Current government has, however, expressed a preference in engaging investors directly. I understand discussions are still underway,” Srivastava said.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 12, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.